Cerus Corporation, a biomedical products company focused in the field of blood safety, has signed a three-year purchase agreement with Bonfils Blood Center for the Intercept Blood System for platelets and plasma.
Bonfils provides blood and blood products to more than 100 hospitals and healthcare facilities across Colorado and beyond, supplying approximately 20,000 platelet and 25,000 plasma units per year. Bonfils is an affiliate of Blood Systems Inc., one of the largest blood product and service providers in the US.
“We are excited to partner with Cerus to make Intercept pathogen reduction another important option for our healthcare clients as we work in collaboration to deliver on our mission to ‘save and enhance lives through transfusion medicine excellence,” said Bryan Krueger, Bonfils Blood Center president and chief executive officer.
“We are pleased to offer the use of Intercept pathogen reduction to enhance the quality of care provided at the hospitals we serve and for the patients for which they provide treatment,” said Tuan Le, MD, medical director and vice president of medical affairs at Bonfils Blood Center.
"Bonfils has been a valuable research partner for us, contributing significantly to studies we've used to support our current FDA approvals and also future product extensions," commented William "Obi" Greenman, Cerus’ president and chief executive officer. "We are pleased to expand this relationship and now become their pathogen reduction supplier."
For more than 70 years, Bonfils Blood Center has held a presence in this community as one of Colorado’s top nonprofit healthcare organisations.